-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Biosciences posts corporate presentation on antiviral pipeline for herpesviruses, hepatitis B and D

PUBT·05/07/2026 22:01:24
Listen to the news
Assembly Biosciences posts corporate presentation on antiviral pipeline for herpesviruses, hepatitis B and D
  • Assembly Biosciences outlined progress across four clinical-stage antiviral programs, highlighting a Gilead collaboration that includes option rights on programs at end of Phase 1 or Phase 2.
  • Gilead exercised its option to license recurrent genital herpes candidates ABI-5366 and ABI-1179 following positive interim Phase 1b data reported in 2025, triggering a USD 35 million payment.
  • Deal terms include eligibility for up to about USD 330 million in milestones per program plus tiered royalties on net sales, with an alternative option for Assembly to take a 40% US profit and cost share in lieu of US milestones and royalties.
  • Phase 2 initiation for ABI-5366 and ABI-1179 is anticipated by end of 2026 under Gilead collaboration, with hepatitis D candidate ABI-6250 expected to enter Phase 2 in Q4 2026.
  • Cash, cash equivalents, and marketable securities totaled about USD 227 million as of March 31, 2026, supporting operations into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.